The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.
 
Josep M. Llovet
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; Eisai; Exelixis; Fortress Biotech; Genentech; Glycotest; Ipsen; Lilly; Merck; Mina Alpha Ltd; Nucleix; Roche; Sirtex Medical
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Ipsen
Patents, Royalties, Other Intellectual Property - iCHAN School of Medicine at Mount Sinai
 
Amit G. Singal
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exact Sciences; Exelixis; Genentech; Glycotest; Roche; Target Pharmasolutions; Wako Diagnostics
Research Funding - Abbvie (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Eisai; Exelixis
 
Augusto Villanueva
Consulting or Advisory Role - Boehringer Ingelheim; Exact Sciences; Gilead Sciences; Guidepoint Global; Natera; NGM Biopharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent EP20140382535 on a method for prognosis of hepatocellular carcinoma; Patent pending PCT/US2018/037579 on methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy; Patent US13124487 on compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders; Small unannotated, non-coding RNAs for the detection of liver cancer
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Ono Pharmaceutical; Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Peter R. Galle
Honoraria - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Chunxiao Wang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Ryan C Widau
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Elena Gonzalez Gugel
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)